Fig. 5From: Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaARQ 531 exhibits in vivo anti-leukemic activity in AML. Kaplan–Meier survival curve in the MOLM-13 disseminated AML xenograft model. Mice were treated with vehicle (N = 7) or 50 mg/kg ARQ 531 Q.D.P.O (N = 8) at 7 days post engraftment until ERCBack to article page